Next Article in Journal
Secular Trends in the Survival of Patients with Laryngeal Carcinoma, 1995–2007
Previous Article in Journal
Access to Oncology Consultation in a Cancer Cohort in Northeastern Ontario
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 2
10.3747/co.22.2247
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Acute Toxicity of Hypofractionated Intensity-Modulated Radiotherapy for Prostate Cancer

by
C.S. Drodge
1,2,
O. Boychak
1,
S. Patel
1,
N. Usmani
1,
J. Amanie
1,
M.B. Parliament
1,
A. Murtha
1,
C. Field
3,
S. Ghosh
4 and
N. Pervez
1,*
1
Division of Radiation Oncology, Cross Cancer Institute, Edmonton, AB, Canada
2
Department of Radiation Oncology, Eastern Health, Dr. H. Bliss Murphy Cancer Centre, St. John’s, NL, Canada
3
Division of Medical Physics, Cross Cancer Institute, Edmonton, AB, Canada
4
Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(2), 76-84; https://doi.org/10.3747/co.22.2247
Submission received: 6 January 2015 / Revised: 3 February 2015 / Accepted: 9 March 2015 / Published: 1 April 2015

Abstract

Background: Dose-escalated hypofractionated radiotherapy (hfrt) using intensity-modulated radiotherapy (imrt), with inclusion of the pelvic lymph nodes (plns), plus androgen suppression therapy (ast) in high-risk prostate cancer patients should improve patient outcomes, but acute toxicity could limit its feasibility. Methods: Our single-centre phase ii prospective study enrolled 40 high-risk prostate cancer patients. All patients received hfrt using imrt with daily mega-voltage computed tomography imaging guidance, with 95% of planning target volumes (ptv68 and ptv50) receiving 68 Gy and 50 Gy (respectively) in 25 daily fractions. The boost volume was targeted to the involved imrt and the prostate (minus the urethra plus 3 mm and minus 3 mm from adjacent rectal wall) and totalled up to 75 Gy in 25 fractions. Acute toxicity scores were recorded weekly during and 3 months after radiotherapy (rt) administration. Results: For the 37 patients who completed rt and the 3-month follow-up, median age was 65.5 years (range: 50–76 years). Disease was organ-confined (T1c–T2c) in 23 patients (62.1%), and node-positive in 5 patients (13.5%). All patients received long-term ast. Maximum acute genitourinary (gu) and gastrointestinal (gi) toxicity peaked at grade 2 in 6 of 36 evaluated patients (16.6%) and in 4 of 31 evaluated patients (12.9%) respectively. Diarrhea and urinary frequency were the chief complaints. Dose–volume parameters demonstrated no correlation with toxicity. The ptv treatment objectives were met in 36 of the 37 patients. Conclusions: This hfrt dose-escalation trial in high-risk prostate cancer has demonstrated the feasibility of administering 75 Gy in 25 fractions with minimal acute gi and gu toxicities. Further follow-up will report late toxicities and outcomes.
Keywords: hypofractionated radiotherapy; intensity-modulated radiotherapy; androgen suppression; high-risk prostate cancer; acute toxicity hypofractionated radiotherapy; intensity-modulated radiotherapy; androgen suppression; high-risk prostate cancer; acute toxicity

Share and Cite

MDPI and ACS Style

Drodge, C.S.; Boychak, O.; Patel, S.; Usmani, N.; Amanie, J.; Parliament, M.B.; Murtha, A.; Field, C.; Ghosh, S.; Pervez, N. Acute Toxicity of Hypofractionated Intensity-Modulated Radiotherapy for Prostate Cancer. Curr. Oncol. 2015, 22, 76-84. https://doi.org/10.3747/co.22.2247

AMA Style

Drodge CS, Boychak O, Patel S, Usmani N, Amanie J, Parliament MB, Murtha A, Field C, Ghosh S, Pervez N. Acute Toxicity of Hypofractionated Intensity-Modulated Radiotherapy for Prostate Cancer. Current Oncology. 2015; 22(2):76-84. https://doi.org/10.3747/co.22.2247

Chicago/Turabian Style

Drodge, C.S., O. Boychak, S. Patel, N. Usmani, J. Amanie, M.B. Parliament, A. Murtha, C. Field, S. Ghosh, and N. Pervez. 2015. "Acute Toxicity of Hypofractionated Intensity-Modulated Radiotherapy for Prostate Cancer" Current Oncology 22, no. 2: 76-84. https://doi.org/10.3747/co.22.2247

APA Style

Drodge, C. S., Boychak, O., Patel, S., Usmani, N., Amanie, J., Parliament, M. B., Murtha, A., Field, C., Ghosh, S., & Pervez, N. (2015). Acute Toxicity of Hypofractionated Intensity-Modulated Radiotherapy for Prostate Cancer. Current Oncology, 22(2), 76-84. https://doi.org/10.3747/co.22.2247

Article Metrics

Back to TopTop